About Cartesian Therapeutics
Pioneering RNA cell therapy for autoimmune disease
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Frederick, Maryland
- Founded
- 2016
- Company type
- Public Company
Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis with plans to initiate a Phase 2 trial in myositis. For more information, please visit www.cartesiantherapeutics.com.
Specialties
- Immunotherapy
- Oncology
- Molecular Biology
- Immunology
- Myasthenia Gravis
- ARDS
- Cell Therapy
- NETs
- Gene Therapy
- Cancer Research
- multiple myeloma
- SLE
- mRNA
- CAR-T
- Systemic lupus erythematosus
- Autoimmunity
- Autoimmune Disease
- and Lupus
Company locations
7495 New Horizon Way, Frederick, Maryland 21703, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
On LinkedIn
- Followers
- 9,090
- People linked to this company
- 95
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.